{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T15:16:20Z","timestamp":1769094980470,"version":"3.49.0"},"reference-count":47,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T00:00:00Z","timestamp":1682812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The calculation of the return on investment (ROI) allows the estimation of the opportunity cost of a series of interventions and can therefore help to make allocative choices. The objective of this study is to estimate the ROI of three vaccinations (HPV for adolescents, HZ for adults, and influenza for the elderly) in the Italian context, considering the impact of increasing vaccination coverage based on target objectives of the National Immunization Plan (PNPV) 2017\u20132019 and accounting for different eligibility criteria of each vaccination. Three separate static cohort models were constructed, including the eligible population for these vaccinations on the basis of the PNPV 2017\u20132019 and following this population until death (lifetime horizon) or until vaccination waning. Each model compares the level of investment at current vaccine coverage rates (current VCRs scenario) with that of optimal NIP target VCRs with a non-vaccination scenario. The ROI for HPV vaccination was the highest among the programs compared and was always above 1 (range: 1.4\u20133.58), while lower values were estimated for influenza vaccination in the elderly (range 0.48\u20130.53) and for vaccination against HZ (range: 0.09\u20130.27). Our analysis showed that a significant proportion of savings generated by vaccination programs occurred outside the NHS perspective and might often not be estimated with other forms of economic evaluation.<\/jats:p>","DOI":"10.3390\/vaccines11050924","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T01:36:27Z","timestamp":1682991387000},"page":"924","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Return on Investment (ROI) of Three Vaccination Programmes in Italy: HPV at 12 Years, Herpes Zoster in Adults, and Influenza in the Elderly"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0111-1246","authenticated-orcid":false,"given":"Marco","family":"Barbieri","sequence":"first","affiliation":[{"name":"York Health Economics Consortium, York YO10 5NQ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9695-7549","authenticated-orcid":false,"given":"Sara","family":"Boccalini","sequence":"additional","affiliation":[{"name":"Sezione di Igiene, Medicina Preventiva, Infermieristica e Sanit\u00e0 Pubblica, Universit\u00e0 degli Studi di Firenze, 50121 Firenze, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4419-7185-2_1","article-title":"The value of vaccination","volume":"697","author":"Bloom","year":"2011","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5945","DOI":"10.1016\/j.vaccine.2007.04.070","article-title":"Do we fully understand the economic value of vaccines?","volume":"25","author":"Drummond","year":"2007","journal-title":"Vaccine"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Jit, M., Hutubessy, R., Png, M.E., Sundaram, N., Audimulam, J., Salim, S., and Yoong, J. (2015). The broader economic impact of vaccination: Reviewing and appraising the strength of evidence. BMC Med., 13.","DOI":"10.1186\/s12916-015-0446-9"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1377\/hlthaff.2015.1088","article-title":"The Social Value of Vaccination Programs: Beyond Cost-Effectiveness","volume":"35","author":"Luyten","year":"2016","journal-title":"Health Aff."},{"key":"ref_5","unstructured":"GAVI.org (2021, December 01). New Evidence Shows Investments in Vaccination Produce Even Greater Returns Than Previously Thought. Available online: https:\/\/www.gavi.org\/vaccineswork\/new-evidence-shows-investments-vaccination-produce-even-greater-returns-previously."},{"key":"ref_6","unstructured":"IVAC (2021, December 01). The Value of Vaccine Programmes. Available online: https:\/\/www.jhsph.edu\/ivac\/wp-content\/uploads\/2021\/02\/FINAL-DRAFT-Vaccine-ROI-Policy-Brief_feb-2021.pdf."},{"key":"ref_7","unstructured":"DOvE (2021, December 01). The Value of Vaccine Programmes. Available online: Vaccineroi.org."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/jech-2016-208141","article-title":"Return on investment of public health interventions: A systematic review","volume":"71","author":"Masters","year":"2017","journal-title":"J. Epidemiol. Community Health"},{"key":"ref_9","unstructured":"Brassel, S., and Steuten, L. (2021, December 01). The Broader Value of Vaccines\u2014The Return on Investment from a Governmental Perspective. OHE Consulting Report, London: Office of Health Economics. Available online: https:\/\/www.ohe.org\/publications\/broader-value-vaccines-return-investment-governmentalperspective."},{"key":"ref_10","unstructured":"Resch, S., Menzies, N., Portnoy, A., Clarke-Deelder, E., O\u2019Keeffe, L., Suharlim, C., and Brenzel, L. (2020). How to Cost Immunisation Programmes: A Practical Guide on Primary Data Collection and Analysis, Harvard T.H. Chan."},{"key":"ref_11","unstructured":"(2021, December 01). Demography in Figures. Available online: https:\/\/demo.istat.it\/index.php."},{"key":"ref_12","unstructured":"(2021, December 01). National Vaccination Prevention Plan 2017\u20132019, Available online: https:\/\/www.salute.gov.it\/portale\/vaccinazioni\/dettaglioContenutiVaccinazioni.jsp?lingua=italiano&id=4828&area=vaccinazioni&menu=vuoto."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9343(97)00177-0","article-title":"Epidemiology of genital human papillomavirus infection","volume":"102","author":"Koutsky","year":"1997","journal-title":"Am. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.jcv.2004.12.008","article-title":"The epidemiology of human papillomavirus infections","volume":"32","author":"Baseman","year":"2005","journal-title":"J. Clin. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s10198-021-01317-w","article-title":"Human papillomavirus in Italy: Retrospective cohort analysis and preliminary vaccination effect from real-world data","volume":"22","author":"Marcellusi","year":"2021","journal-title":"Eur. J. Health Econ."},{"key":"ref_16","unstructured":"(2021, December 01). Papilloma Virus (HPV) Vaccination\u2014Vaccination Coverage as of 31 December 2019, Available online: https:\/\/www.salute.gov.it\/portale\/documentazione\/p6_2_8_3_1.jsp?lingua=italiano&id=27."},{"key":"ref_17","unstructured":"(2021, December 01). Mortality Tables. Available online: http:\/\/dati.istat.it\/index.aspx?queryid=7283."},{"key":"ref_18","unstructured":"(2021, December 01). RCP EMA Gardasil. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/gardasil."},{"key":"ref_19","unstructured":"(2021, December 01). RCP EMA Gardasil9. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/gardasil-9."},{"key":"ref_20","unstructured":"FDA (2021, December 01). Label Database for Gardasil9. 21 August 2020 Update, Available online: https:\/\/www.fda.gov\/media\/90064\/download."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis","volume":"8","author":"Georges","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13027-017-0129-6","article-title":"Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe","volume":"12","author":"Hartwig","year":"2017","journal-title":"Infect. Agent Cancer"},{"key":"ref_23","unstructured":"Gazzetta Ufficiale (2022, March 10). Remuneration of Acute Hospital Care, Rehabilitation and Post-Acute Long-Term Hospital Care and Outpatient Specialist Care. GU Serie Generale n. 23 del 28-01-2013\u2014Suppl. Ordinario n. 8. Official Document of Ministry of Health. Available online: https:\/\/www.gazzettaufficiale.it."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Baio, G., Capone, A., Marcellusi, A., Mennini, F.S., and Favato, G. (2012). Economic burden of human papillomavirus-related diseases in Italy. PLoS ONE, 7, Erratum in PLoS ONE 2013, 8.","DOI":"10.1371\/annotation\/39ddb7a9-3e7e-4544-a226-2e2b872a5116"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/030089160909500203","article-title":"Incidence of invasive cervical cancer and direct costs associated with its management in Italy","volume":"95","author":"Ricciardi","year":"2009","journal-title":"Tumori"},{"key":"ref_26","unstructured":"(2021, December 01). FARMADATI. Available online: https:\/\/www.farmadati.it\/."},{"key":"ref_27","unstructured":"(2021, December 01). Abstract Presented at ISPOR Italy Rome Chapter, Mennini et al., \u2018HPV9-Related Diseases: The Economic Burden on the Social Security System in Italy\u2019. Available online: https:\/\/tools.ispor.org\/research_pdfs\/60\/pdffiles\/PIN11.pdf."},{"key":"ref_28","first-page":"ciab629","article-title":"The Adjuvanted Recombinant Zoster Vaccine Confers Long-term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase III Clinical Trials (ZOE-50 and ZOE-70)","volume":"20","author":"Boutry","year":"2021","journal-title":"Clin. Infect Dis."},{"key":"ref_29","unstructured":"(2021, December 01). ISTAT MULTISCOPE. Available online: https:\/\/www.istat.it\/it\/archivio\/129916."},{"key":"ref_30","unstructured":"SER (2021, December 01). Epidemiological Report on Chronic Diseases in Veneto Data Year 2018. Available online: https:\/\/www.ser-veneto.it\/public\/Rapporto_epidemiologico_malattie_croniche_Veneto_2018.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50\u201359 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin. Infect Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1016\/j.vaccine.2019.09.028","article-title":"Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry\/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomised trials","volume":"37","author":"Willer","year":"2019","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/21645515.2017.1264834","article-title":"Incidence of herpes zoster and post-herpetic neuralgia in Italy: Results from a 3-years population-based study","volume":"13","author":"Alicino","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4161\/hv.36160","article-title":"Evaluation of the economic burden of Herpes Zoster (HZ) infection","volume":"11","author":"Panatto","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1017\/S0266462320000069","article-title":"Estimating the fiscal impact of three vaccination strategies in Italy","volume":"36","author":"Ruggeri","year":"2020","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1017\/S0266462316000337","article-title":"Cost-effectiveness analysis of Herpes Zoster Vaccination in italian elderly persons","volume":"32","author":"Coretti","year":"2016","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_37","unstructured":"(2021, December 01). La Sorveglianza Passi d\u2019Argento. Available online: https:\/\/www.epicentro.iss.it\/passi-argento."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1080\/21645515.2018.1438792","article-title":"Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly population","volume":"14","author":"Capri","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s100960000376","article-title":"Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom","volume":"19","author":"Meier","year":"2000","journal-title":"Eur. J. Clin. Microbiol. Infect Dis."},{"key":"ref_40","first-page":"1","article-title":"Pharmacoeconomic evaluation of the MF59--adjuvanted influenza vaccine in the elderly population in Italy","volume":"52","author":"Iannazzo","year":"2011","journal-title":"J. Prev. Med. Hyg."},{"key":"ref_41","unstructured":"(2021, December 01). Nomenclatore Tariffario Delle Prestazioni Aggiuntive, Accordo Collettivo Nazionale Medici Generici, 23 Marzo 2005. Available online: http:\/\/www.sisac.info\/aree\/www.sisac.info\/resources\/MEDICINA_GENERALE\/ACN_testo_integrato.pdf."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/aje\/kwm375","article-title":"Time lines of infection and disease in human influenza: A review of volunteer challenge studies","volume":"167","author":"Carrat","year":"2008","journal-title":"Am. J. Epidemiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4161\/hv.3.1.3657","article-title":"Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age","volume":"3","author":"Marchetti","year":"2007","journal-title":"Hum. Vaccines"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/fampra\/18.6.629","article-title":"The incidence, natural history and associated outcomes of influenza-like illness and clinical influenza in Italy","volume":"18","author":"Sessa","year":"2001","journal-title":"Fam. Pract."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jinf.2011.02.015","article-title":"Clinical manifestations and socio-economic impact of influenza among healthy children in the community","volume":"62","author":"Esposito","year":"2011","journal-title":"J. Infect."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S1473-3099(16)00129-8","article-title":"Variable influenza vaccine effectiveness by subtype: A systematic review and meta-analysis of test-negative design studies","volume":"16","author":"Belongia","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1016\/j.vaccine.2017.06.038","article-title":"Rationale for two influenza B lineages in seasonal vaccines: A meta-regression study on immunogenicity and controlled field trials","volume":"35","author":"Beyer","year":"2017","journal-title":"Vaccine"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/5\/924\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:27:33Z","timestamp":1760124453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/5\/924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,30]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["vaccines11050924"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11050924","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,30]]}}}